Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N=7914) [0.03%]
WSG ADAPT-HR+/HER2-和ADAPTcycle试验中短期新辅助内分泌治疗后预测内分泌反应的临床和分子生物标志物（n=7914）
O Gluz,U Nitz,M Christgen et al.
O Gluz et al.
Background: Low Ki67 after short preoperative endocrine treatment (ET) indicates a favorable prognosis in HR+/HER2- early breast cancer (eBC). We investigated predictors of ET-response in the WSG ADAPT-HR+/HER2- and ADAPT...
DART (NCI/SWOG S1609): Comprehensive Final Results from Dual Checkpoint Inhibition with CTLA-4 and PD-1 Blockade in Rare Cancers [0.03%]
NCI/SWOG S1609：DART研究——CTLA-4和PD-1抑制联合治疗罕见肿瘤的最终结果
S P Patel,M Othus,Y K Chae et al.
S P Patel et al.
Background: We summarize final results of the NCI/SWOG S1609 trial, whose objective was to evaluate efficacy signals across 53 refractory rare cancer cohorts treated with dual CTLA-4 and PD-1 inhibition. ...
A Simple Plan: Chemotherapy-Sparing Approaches to Early Stage and Regional Seminoma and Non-Seminoma [0.03%]
简化治疗：早期和局部精原细胞瘤和非精原细胞瘤的无需化疗治疗方法
L Nappi,A Thor,T Tandstad et al.
L Nappi et al.
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up [0.03%]
结直肠癌转移的诊断、治疗和随访：欧洲肿瘤内科学会临床实践指南
C Cremolini,M Chalabi,E Elez et al.
C Cremolini et al.
Genomic Determinants of Response to Alpelisib Plus Fulvestrant in the SOLAR-1 Trial [0.03%]
SOLAR-1试验中阿培利塞联合氟维司群治疗的基因组决定因素
D Juric,H S Rugo,A Reising et al.
D Juric et al.
Background: Approximately 40% of patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced breast cancer (ABC) have PIK3CA alterations, which contributes to endocri...
The Curious Incident of the T-DXd Arm Killed at (DESTINY-Breast) Eleven O'Clock: Statistical Concerns [0.03%]
T-DXd臂在 DESTINY-Breast十一點被杀死：统计学担忧
Armando Orlandi
Armando Orlandi
Corrigendum to "Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial": [Ann Oncol 36 (2025) 775-785] [0.03%]
"帕博利珠单抗联合化疗治疗转移性非小细胞肺癌的皮下给药与静脉给药比较：3475A-D77三期临床试验的校正说明"[Ann Oncol 36 (2025) 775-785]
E Felip,C I Rojas,M Schenker et al.
E Felip et al.
Corrigendum to "Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer": [Ann Oncol 36 (2025) 76-88] [0.03%]
“BMS-986365（CC-94676）是一种双雄激素受体配体靶向降解剂和拮抗剂，在接受过多线治疗的转移性去势抵抗性前列腺癌患者中的安全性和临床活性”一文勘误：[Ann Oncol 36 (2025) 76-88]
D E Rathkopf,M R Patel,A D Choudhury et al.
D E Rathkopf et al.
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial [0.03%]
用于治疗初治的晚期三阴性乳腺癌患者的datopotamab deruxtecan（TROPION-Breast02）：一项随机、开放标签、国际多中心III期试验
R Dent,Z Shao,P Schmid et al.
R Dent et al.
Background: Prognosis is poor and treatment options are limited for patients with previously untreated, advanced triple-negative breast cancer (TNBC), especially for those who are not candidates for immunotherapy. ...